CC
BMY.RT

Casdin Capital’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Casdin Capital’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-6,250,000
Closed -$4.31M – 56
2020
Q4 		$4.31M Hold
6,250,000
– – 0.13% 49
2020
Q3 		$14.1M Buy
6,250,000
+3,300,000
+112% +$9.42M 0.63% 33
2020
Q2 		$10.6M Buy
2,950,000
+450,000
+18% +$1.62M 0.63% 34
2020
Q1 		$9.5M Buy
2,500,000
+1,000,000
+67% +$3.29M 1.01% 30
2019
Q4 		$4.51M Buy
+1,500,000
New +$3.9M 0.42% 31

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $77B AUM 10.33% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $245M AUM 15.03% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Casdin Capital's BMY.RT Position: Q1 2021 in Review

Casdin Capital sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 6,250,000 shares — an estimated $4.31M sold.

Casdin Capital first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $14.1M in Q3 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Casdin Capital reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Casdin Capital sold 6,250,000 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $4.31M.
  • Casdin Capital first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Casdin Capital's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $14.1M in Q3 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Casdin Capital's 13F filing for Q1 2021, filed 17 May 2021.